Campione, E.; Zarabian, N.; Cosio, T.; Borselli, C.; Artosi, F.; Cont, R.; Sorge, R.; Shumak, R.G.; Costanza, G.; Rivieccio, A.;
et al. Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis. Pharmaceuticals 2024, 17, 989.
https://doi.org/10.3390/ph17080989
AMA Style
Campione E, Zarabian N, Cosio T, Borselli C, Artosi F, Cont R, Sorge R, Shumak RG, Costanza G, Rivieccio A,
et al. Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis. Pharmaceuticals. 2024; 17(8):989.
https://doi.org/10.3390/ph17080989
Chicago/Turabian Style
Campione, Elena, Nikkia Zarabian, Terenzio Cosio, Cristiana Borselli, Fabio Artosi, Riccardo Cont, Roberto Sorge, Ruslana Gaeta Shumak, Gaetana Costanza, Antonia Rivieccio,
and et al. 2024. "Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis" Pharmaceuticals 17, no. 8: 989.
https://doi.org/10.3390/ph17080989
APA Style
Campione, E., Zarabian, N., Cosio, T., Borselli, C., Artosi, F., Cont, R., Sorge, R., Shumak, R. G., Costanza, G., Rivieccio, A., Gaziano, R., & Bianchi, L.
(2024). Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis. Pharmaceuticals, 17(8), 989.
https://doi.org/10.3390/ph17080989